This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Greenberg: What You May Have Missed

SAN DIEGO (TheStreet) -- Here's what you may have missed over the past week, including takes on Nu Skin, Clean Harbors and pharmaceutical mega mergers.

-- Keeping an Eye on Nu Skin

-- Analyzing the Analyst on Clean Harbor

-- Dueling Reports on Pharma Mega Mergers

It was a light week as I am working on new stories, but here is a roundup from last week's Reality Check. Plus, as an added bonus, there is a new red flag.

KEEP AN EYE ON NU SKIN: The next date that counts will be March 18, which is the deadline for the company to file its delayed 10-K. As I wrote on here last week, the company disclosed that its audit committee had hired "outside counsel" to help with an internal review of Nu Skin's (NUS - Get Report) China operations. But why would the audit committee be involved in a review of the company's China operation -- whose operations are being probed by the Chinese government? And why would the audit committee hire outside counsel?

This update: Over the past week, Nu Skin, which didn't take questions on its recent fourth-quarter earnings call, cancelled two investor presentations. The bigger question, now that the company is halfway through its first quarter, is what impact the China investigation has had on the growth Nu Skin's Chinese sales force -- its biggest area of growth.

Must Read: Greenberg: What You May Have Missed

I'm adding Nu Skin to the Watch List with a red flag as of Monday's close. The stock has already fallen by half but, unless its China growth can resume and continue on its prior path, its model faces an unusually high level of risk. Reminder: This stock traded at $41 a year ago. It closed at $76 on Monday.

ANALYZING THE ANALYST ON CLEAN HARBORS: It was noteworthy that Raymond James analyst Bill Fisher upgraded Clean Harbors (CLH - Get Report), after yet another horrible quarter, to a strong buy from the equivalent of a hold. Much of his recommendation, as I wrote here on Reality Check last week, appeared to be based on his belief that the company "seemed to allude that the seismic portion of sales (~one-third)" from its oil and gas and refining operations "may not be core to the operation." Me: Seemed to allude?

MEANWHILE, ON THE MEGA-MERGER FRONT: I didn't write about this over the past week, but The Value Investment Institute weighed in on the new wave of pharmaceutical rollups, which has been bolstering the shares of Valeant Pharma (VRX - Get Report), Endo International (ENDP) and Actavis (ACT). (Hint: It's troubled by the trend.) Not to be outdone, consulting firm McKinsey wrote a paper on "why pharma mega mergers work." Hint: It's not troubled by the trend.

Reality check: Valeant CEO Michael Pearson, until joining Valeant in 2008, hailed from (drumroll!) McKinsey. Interpret that as you will.

-- Written by Herb Greenberg in San Diego

Herb Greenberg, editor of Herb Greenberg's Reality Check, is a contributor to CNBC. He does not own shares, short or trade shares in an individual corporate security. He can be reached at


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Herb's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs